var title_f2_18_2336="Episodic cortisol in Cushings";
var content_f2_18_2336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Episodic cortisol secretion in Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 311px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serum cortisol concentrations throughout the day in patients with different forms of Cushing's syndrome. There is episodic hormone release in both ACTH-dependent and ACTH-independent (adrenal adenoma) forms of the syndrome. To convert serum cortisol to nmol/L, multiply by 27.6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology.&nbsp;J Clin Endocrinol Metab 1973; 36:906.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2336=[""].join("\n");
var outline_f2_18_2336=null;
var title_f2_18_2337="Ultrasound of normal abdominal aorta and aortic aneurysm";
var content_f2_18_2337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Ultrasound of normal abdominal aorta and aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ultrasound in longitudinal view shows a normal abdominal aorta (A), which is contrasted with a similar view of an aorta in a patient with a 7.7 cm infrarenal abdominal aortic aneurysm (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2337=[""].join("\n");
var outline_f2_18_2337=null;
var title_f2_18_2338="Aluminum sulfate calcium acetate: Pediatric drug information";
var content_f2_18_2338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum sulfate calcium acetate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/7/127?source=see_link\">",
"    see \"Aluminum sulfate calcium acetate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/45/20180?source=see_link\">",
"    see \"Aluminum sulfate calcium acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4588854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Domeboro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1044949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1044946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/7/127?source=see_link\">",
"      see \"Aluminum sulfate calcium acetate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical: Soak the affected area in the solution 2-4 times/day for 15-30 minutes or apply wet dressing soaked in the solution 2-4 times/day for 30-minute treatment periods; rewet dressing with solution every few minutes to keep it moist",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14448641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablet for solution: 1 tablet/pint [1:40 dilution]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1044952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Keep away from eyes, external use only; one powder packet dissolved in 16 oz of water makes a modified Burow's solution equivalent to a 1:40 dilution, 2 packets: 1:20 dilution, 3 packets: 1:13 dilution. When used as a compress or wet dressing, soak a clean soft cloth in the solution. Apply cloth loosely to affected area for 15-30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1044951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Astringent wet dressing for relief of inflammatory conditions of the skin and to reduce weeping that may occur in dermatitis; relieve minor skin irritations due to poison ivy, poison oak, poison sumac, insect bites, athlete&rsquo;s foot, and rashes caused by soaps, detergents, cosmetics, or jewelry",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F14198742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local: Irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1044954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with topical collagenase",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1044945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use plastic or other impervious material to prevent evaporation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F238199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F238201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13383 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2338=[""].join("\n");
var outline_f2_18_2338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4588854\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044949\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044946\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14448641\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044952\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044951\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14198742\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044954\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044945\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298718\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238199\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238201\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13383\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13383|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/7/127?source=related_link\">",
"      Aluminum sulfate calcium acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/45/20180?source=related_link\">",
"      Aluminum sulfate calcium acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_18_2339="Preretinal hemorrhages";
var content_f2_18_2339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preretinal hemorrhages",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A preretinal (subhyaloid) hemorrhage develops when blood escapes into the potential space between retina and vitreous. A preretinal hemorrhage typically is larger than other retinal hemorrhages. Because it is anterior to the retina, a preretinal hemorrhage obscures underlying retinal vessels. In an erect patient, red cells settle, creating a horizontal line of demarcation between plasma above and cells below.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2339=[""].join("\n");
var outline_f2_18_2339=null;
var title_f2_18_2340="Doxycycline hyclate periodontal extended-release liquid: Drug information";
var content_f2_18_2340=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxycycline hyclate periodontal extended-release liquid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/28/8644?source=see_link\">",
"    see \"Doxycycline hyclate periodontal extended-release liquid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atridox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atridox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Tetracycline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Periodontitis:",
"     </b>",
"     Subgingival application: Dose depends on size, shape and number of pockets treated. Contains 50 mg doxycycline hyclate per 500 mg of formulation in each final blended syringe product. Application may be repeated four months after initial treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Atridox&reg; subgingival controlled-release product:",
"     </i>",
"     The delivery system consists of 2 separate syringes in a single pouch. Syringe A contains 450 mg of a bioabsorbable polymer gel; syringe B contains doxycycline hyclate 50 mg. To prepare for instillation, couple syringe A to syringe B. Inject contents of syringe A (purple stripe) into syringe B, then push contents back into syringe A. Repeat this mixing cycle at a rate of one cycle per second for 100 cycles. If syringes are stored prior to use (a maximum of 3 days), repeat mixing cycle 10 times before use. After appropriate mixing, contents should be in syringe A. Holding syringes vertically, with syringe A at the bottom, pull back on the syringe A plunger, allowing contents to flow down barrel for several seconds. Uncouple syringes and attach enclosed blunt cannula to syringe A. Local anesthesia is not required for placement. Cannula tip may be bent to resemble periodontal probe and used to explore pocket. Express product from syringe until pocket is filled. To separate tip from formulation, turn tip towards the tooth and press against tooth surface to achieve separation. An appropriate dental instrument may be used to pack gel into the pocket. Pockets may be covered with either Coe-Pak&trade; or Octyldent&trade; dental adhesive.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, subgingival, as hyclate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atridox&reg;: 10% (4 units [DSC], 6 units) [strength expressed as final blended product of Syringe A (controlled release delivery vehicle 450 mg) and Syringe B (doxycycline hyclate 50 mg)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atridox&reg; subgingival controlled-release product: The delivery system consists of 2 separate syringes in a single pouch. Syringe A contains 450 mg of a bioabsorbable polymer gel; syringe B contains doxycycline hyclate 50 mg. To prepare for instillation, couple syringe A to syringe B. Inject contents of syringe A (purple stripe) into syringe B, then push contents back into syringe A. Repeat this mixing cycle at a rate of one cycle per second for 100 cycles. If syringes are stored prior to use (a maximum of 3 days), repeat mixing cycle 10 times before use. After appropriate mixing, contents should be in syringe A. Holding syringes vertically, with syringe A at the bottom, pull back on the syringe A plunger, allowing contents to flow down barrel for several seconds. Uncouple syringes and attach enclosed blunt cannula to syringe A. Local anesthesia is not required for placement. Cannula tip may be bent to resemble periodontal probe and used to explore pocket. Express product from syringe until pocket is filled. To separate tip from formulation, turn tip towards the tooth and press against tooth surface to achieve separation. An appropriate dental instrument may be used to pack gel into the pocket. Pockets may be covered with either Coe-Pak&trade; or Octyldent&trade; dental adhesive.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used exclusively in dental applications",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Discoloration of teeth in children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare adverse effects of tetracyclines: Anaphylaxis, dysphagia, esophageal ulceration (if capsule forms are taken before lying down), exacerbations of SLE, exfoliative dermatitis, glossitis, hemolytic anemia, hepatotoxicity, neutropenia, photosensitivity, rash, thrombocytopenia, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Doxycycline periodontal gel (Atridox&reg;): The adverse effects reported in clinical trials were similar in incidence between doxycycline-containing product and vehicle alone. In addition, these effects were comparable to standard therapies including scaling and root planing or oral hygiene. Events associated with application reported with an incidence &gt;1% included: gum discomfort (18%), toothache (14%), periodontal abscess (10%), tooth sensitivity (8%), broken tooth (5%), tooth mobility (2%), endodontic abscess (2%) and jaw pain (1%). Systemic adverse events included headache (27%), muscle aches (7%), diarrhea (3%), upset stomach (4%), and nausea (2%). Although there is no known relationship between doxycycline and hypertension, unspecified essential hypertension was noted in 1.6% of the doxycycline gel group, as compared to 0.2% in the vehicle group. Allergic reactions to the vehicle were also reported in two patients.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxycycline, tetracycline or any component of the formulation; children &lt;8 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age) unless other drugs are not likely to be effective or are contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Do not use during pregnancy. In addition   to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For subgingival application: This product has not been evaluated or tested in immunocompromised patients, in patients with oral candidiasis, or in conditions characterized by severe periodontal defects with little remaining periodontium. May result in overgrowth of nonsusceptible organisms, including fungi. Effects of treatment &gt;6 months have not been evaluated. Has not been evaluated for use in regeneration of alveolar bone.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exposure to tetracyclines during the second or third trimester may cause permanent discoloration of the teeth. Most reports do not show an increase risk for teratogenicity with the exception of a potential small increased risk for cleft palate or esophageal atresia/stenosis. Serum concentrations following subgingival use are significantly less than with oral tablets.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13882185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13882184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines, including oral doxycycline, are excreted in breast milk and therefore, breast-feeding is not recommended by the manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Doxycycline is less bound to the calcium in maternal milk which may lead to increased absorption compared to other tetracyclines. Only minimal amounts of oral doxycycline are excreted in human milk and the relative amount of tooth staining has been reported to be lower when compared to other tetracycline analogs. Nondose-related effects could include modification of bowel flora. Serum concentrations following subgingival use are significantly less than with oral tablets.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F163394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food, milk, or water.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F854888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atridox&reg; (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Doxycycline inhibits collagenase",
"     <i>",
"      in vitro",
"     </i>",
"     and has been shown to inhibit collagenase in the gingival crevicular fluid in adults with periodontitis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic absorption from dental subgingival gel may occur, but is limited by the slow rate of dissolution from this formulation over 7 days.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8905 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2340=[""].join("\n");
var outline_f2_18_2340=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854887\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163407\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163398\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163399\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163388\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163376\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163390\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163389\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163405\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163393\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163379\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299234\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163383\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163385\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882183\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882185\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882184\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163394\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854888\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163378\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163392\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8905|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/28/8644?source=related_link\">",
"      Doxycycline hyclate periodontal extended-release liquid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_18_2341="LLL atelectasis II";
var content_f2_18_2341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic left lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic atelectasis of the left lower lobe due to previous pneumonia. A triangular opacity is faintly visible in the retrocardiac region (black arrows. The left hilum is displaced caudad. The residual left lung is hyperlucent. A band of opacity, called the top of the knob sign, is present around the aortic arch (white arrow); this finding is due to mediastinal shift to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2341=[""].join("\n");
var outline_f2_18_2341=null;
var title_f2_18_2342="Aflibercept (ziv-aflibercept) (systemic): Drug information";
var content_f2_18_2342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aflibercept (ziv-aflibercept) (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/41/37524?source=see_link\">",
"    see \"Aflibercept (ziv-aflibercept) (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14787449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14933262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zaltrap&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14787442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14857084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Colorectal cancer, metastatic:",
"     </b>",
"     I.V.: 4 mg/kg every 2 weeks (in combination with fluorouracil, leucovorin, and irinotecan [FOLFIRI]), continue until disease progression or unacceptable toxicity",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14857085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14857087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, need for adjustment is not likely because  exposure in patients with mild, moderate, and severe impairment was similar to that of patients with normal renal function.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14857088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild (total bilirubin &gt;1-1.5 times ULN) to moderate (total bilirubin &gt;1.5-3 times ULN) impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, need for adjustment is not likely because exposure was similar to that of patients with normal hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment (total bilirubin &gt;3 times ULN): No dosage adjustment provided in the manufacturer&rsquo;s labeling (no data available).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F14857086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Arterial thrombotic events:",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Fistula formation:",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Gastrointestinal perforation:",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hemorrhage, severe:",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hypertension:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Recurrent or severe hypertension: Temporarily withhold treatment until controlled and then resume with a permanent dose reduction to 2 mg/kg every 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hypertensive crisis or hypertensive encephalopathy: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Neutropenia:",
"     </i>",
"     Temporarily withhold treatment until ANC is &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Renal effects:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Proteinuria (&ge;2 g/24 hours): Temporarily withhold treatment until proteinuria &lt;2 g/24 hours and then resume at previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Recurrent proteinuria: Temporarily withhold treatment until proteinuria &lt;2 g/24 hours and then resume with a permanent dose reduction to 2 mg/kg every 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nephrotic syndrome or thrombotic microangiopathy: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Reversible posterior leukoencephalopathy syndrome (RPLS):",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Surgery/wound healing impairment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Elective surgery: Temporarily withhold treatment for at least 4 weeks prior to elective surgery; do not resume until at least 4 weeks after major surgery AND until wound is fully healed; for minor surgery (eg, biopsy, central venous port placement, tooth extraction), may be resumed after wound is fully healed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Wound healing impaired: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     For toxicities related to FOLFIRI, refer to individual Fluorouracil or Irinotecan monographs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14934219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaltrap&reg;: 25 mg/mL (4 mL, 8 mL) [contains sucrose 20%; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14857062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14857089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 1 hour. Do not administer I.V. push or bolus. Administer prior to any FOLFIRI component. Do not administer other medications through the same intravenous line.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Infuse via a 0.2 micron polyethersulfone filter; do not use filters made of polyvinylidene fluoride (PVDF) or nylon. Administer with one of the following types of infusion sets: Polyvinyl chloride (PVC) containing DEHP, DEHP-free PVC containing trioctyl-trimellitate (TOTM), polypropylene, polyethylene lined PVC, or polyurethane.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14857076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS; do not mix with or infuse in the same I.V. line with other products",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14787443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic colorectal cancer (in combination with fluorouracil, leucovorin, and irinotecan [FOLFIRI]) in patients who are resistant to or have progressed on an oxaliplatin-based regimen",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14857061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ziv-aflibercept may be confused with aflibercept",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14943701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reactions reported in combination therapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (41%; grades 3/4: 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (48%), dysphonia (25%), headache (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Palmar-plantar erythrodysesthesia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (69%), stomatitis (50%), appetite decreased (32%), weight loss (32%), abdominal pain (27%), upper abdominal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (78%; grades 3/4: 16%), neutropenia (67%; grades 3/4: 37%), thrombocytopenia (48%; grades 3/4: 3%), bleeding (38%; grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (62%), ALT increased (50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (62%; grades 3/4: 8%), creatinine increased (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (28%), dyspnea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (46%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Venous thromboembolic events (9%), arterial thromboembolic events (3%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Reversible posterior encephalopathy syndrome (RPLS) (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperpigmentation (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Hemorrhoids (6%), proctalgia (5%), rectal hemorrhage (5%), gastrointestinal perforation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (grades 3/4: 4%), neutropenic infection/sepsis (grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Nephrotic syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Oropharyngeal pain (8%), rhinorrhea (6%), pulmonary embolism (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (3%), fistula formation (2%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Hypersensitivity reactions, thrombotic microangiopathy, wound healing impaired",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14857068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14857069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: A higher incidence of neutropenia and complications due to neutropenia (neutropenic fever and infection) occurred in patients receiving ziv-aflibercept. Leukopenia and thrombocytopenia were also observed in clinical trials. Monitor blood counts (baseline and prior to each cycle); delay treatment until ANC is &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diarrhea: Severe diarrhea and dehydration have been reported. The incidence of diarrhea is increased in patients &ge;65 years of age; monitor elderly patients closely for diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fistula formation: The risk for gastrointestinal (GI) and non-GI fistulas is increased with ziv-aflibercept. Fistula sites have included anal, enterovesical, enterocutaneous, colovaginal and intestinal. Discontinue in patients who develop fistula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal perforation:",
"     <b>",
"      [U.S. Boxed Warning]: Severe or fatal GI perforation is a possibility; discontinue ziv-aflibercept if GI perforation occurs.",
"     </b>",
"     Monitor for signs/symptoms of GI perforation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hemorrhage: The risk for hemorrhage is increased with ziv-aflibercept.",
"     <b>",
"      [U.S. Boxed Warning]: Severe and occasionally fatal hemorrhage, including GI bleeding, has been reported with ziv-aflibercept/FOLFIRI. Monitor for signs and symptoms of GI and other severe bleeding events. Do not administer to patients with severe hemorrhage.",
"     </b>",
"     Discontinue if severe hemorrhage develops. Hemorrhagic events have also included hematuria, postprocedure hemorrhage, intracranial hemorrhage, and pulmonary hemorrhage/hemoptysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: The risk for grades 3/4 hypertension is increased. Onset is generally within the first 2 treatment cycles. Monitor blood pressure every 2 weeks (more frequently if clinically indicated). Treat with appropriate antihypertensive therapy (may require adjustment of existing antihypertensives). Temporarily withhold treatment with uncontrolled hypertension; may reinitiate with permanent dose reduction when controlled. Discontinue for hypertensive crisis or encephalopathy. Patients with NYHA class III or IV heart failure were excluded from clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Proteinuria/nephrotic syndrome: Proteinuria, nephrotic syndrome, and thrombotic microangiopathy (TMA) have been associated with ziv-aflibercept. Evaluate for proteinuria during treatment with urine dipstick and urinary protein creatinine ratio (UPCR); if UPCR &gt;1, obtain 24-hour urine collection. Withhold ziv-aflibercept for proteinuria &ge;2 g/day; for recurrent proteinuria, withhold treatment until &lt;2 g/day and then resume with permanent dose reduction. Discontinue treatment for nephrotic syndrome or TMA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome (RPLS): Cases of RPLS have been reported. Confirm diagnosis with MRI; discontinue ziv-aflibercept if verified. Symptoms generally resolve or improve within days, although persistent neurologic symptoms and death have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolism: Arterial thrombotic events (ATE), including transient ischemic attack, cerebrovascular accidents, and angina have occurred. Discontinue ziv-aflibercept in patients who experience ATEs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Wound healing impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Severely compromised wound healing may occur with ziv-aflibercept/FOLFIRI. Discontinue ziv-aflibercept with compromised wound healing. Withhold ziv-aflibercept at least 4 weeks prior to elective surgery. Do not resume treatment until at least 4 weeks after major surgery AND until the surgical wound is completely healed.",
"     </b>",
"     For minor surgeries (eg, central venous access port placement, biopsy, or tooth extraction), ziv-aflibercept may be resumed or initiated as soon as the surgical wound is fully healed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Certain adverse events, such as diarrhea and dehydration, occurred at a higher incidence in elderly compared to younger adults; monitor closely during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14975299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14975297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14857064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14857065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies with doses providing systemic exposure equivalent to ~30% of a human dose. The incidence of fetal malformations increased with increasing doses. Patients (male and female) should use effective contraception during therapy and for at least 3 months following treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14857066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14857067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if ziv-aflibercept is excreted into breast milk. Due to the potential for adverse events in a nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zaltrap Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/4 mL (4 mL): $1920.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/8 mL (8 mL): $3840.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14857092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and prior to each cycle); urine protein (dipstick analysis and urinary protein creatinine ratio [UPCR], obtain 24-hour urine collection if UPCR &gt;1); blood pressure (every 2 weeks; more frequently if clinically indicated); monitor for signs/symptoms of hemorrhage or GI perforation; monitor elderly patients closely for diarrhea and/or dehydration. Monitor wounds for healing impairment.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14857077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also known as VEGF-trap, ziv-aflibercept is a recombinant fusion protein which is comprised of portions of binding domains for vascular endothelial growth factor (VEGF) receptors 1 and 2, attached to the Fc portion of human IgG1. Ziv-aflibercept acts as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF) which prevent VEGF receptor binding/activation to their receptors (an action critical to angiogenesis), thus leading to antiangiogenesis and tumor regression.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14857079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: ~6 days (range: 4-7 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allegra CJ, Lakomy R, Tabernero J, et al, &ldquo;Effects of Prior Bevacizumab (B) Use on Outcomes From the VELOUR Study: A Phase III Study of Aflibercept (Afl) and FOLFIRI in Patients (Pts) With Metastatic Colorectal Cancer (Mcrc) After Failure of an Oxaliplatin Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):3505 [abstract 3505 from ASCO 2012 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaya A and Tse V, &ldquo;A Preclinical and Clinical Review of Aflibercept for the Management of Cancer,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2012, 38(5):484-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/18/2342/abstract-text/22264850/pubmed\" id=\"22264850\" target=\"_blank\">",
"        22264850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isambert N, Freyer G, Zanetta S, et al, &ldquo;Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination With Docetaxel in Patients With Advanced Solid Tumors,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2012, 18(6):1743-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/18/2342/abstract-text/22261804/pubmed\" id=\"22261804\" target=\"_blank\">",
"        22261804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joulian F, Van Cutsem E, Iqbal SU, et al, &ldquo;Aflibercept versus Placebo in Combination With FOLFIRI in Previously Treated Metastatic Colorectal Cancer (Mcrc): Mean Overall Survival (OS) Estimation From a Phase III Trial (VELOUR),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):3602 [abstract 3602 from ASCO 2012 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockhart AC, Rothenberg ML, Dupont J, et al, &ldquo;Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(2):207-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/18/2342/abstract-text/19949018/pubmed\" id=\"19949018\" target=\"_blank\">",
"        19949018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tabernero J, Allegra CJ, Rougier PR, et al, &ldquo; Meta-Analysis of Anti-VEGF Class Adverse Events From Three Double-Blind (db) Placebo (pbo)-Controlled Phase III Trials With IV Aflibercept (Afl),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):3579 [abstract 3579 from ASCO 2012 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Tabernero J, Lakomy R, et al, \"Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(28):3499-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/18/2342/abstract-text/22949147/pubmed\" id=\"22949147\" target=\"_blank\">",
"        22949147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86239 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2342=[""].join("\n");
var outline_f2_18_2342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787449\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933262\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787442\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857084\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857085\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857087\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857088\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857086\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14934219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857062\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857089\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857076\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787443\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857061\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943701\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857068\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857069\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975299\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975297\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857064\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857065\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857066\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857067\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570448\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857092\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857077\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14857079\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/18/27939?source=related_link\">",
"      Aflibercept (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/44/25283?source=related_link\">",
"      Aflibercept (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/41/37524?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_18_2343="Morphea stages";
var content_f2_18_2343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Stages of morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 675px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2343=[""].join("\n");
var outline_f2_18_2343=null;
var title_f2_18_2344="Meloxicam: Pediatric drug information";
var content_f2_18_2344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meloxicam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"    see \"Meloxicam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/50/26405?source=see_link\">",
"    see \"Meloxicam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mobic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Meloxicam&reg;;",
"     </li>",
"     <li>",
"      Auro-Meloxicam;",
"     </li>",
"     <li>",
"      Ava-Meloxicam;",
"     </li>",
"     <li>",
"      CO Meloxicam;",
"     </li>",
"     <li>",
"      Dom-Meloxicam;",
"     </li>",
"     <li>",
"      Mobicox&reg;;",
"     </li>",
"     <li>",
"      Mobic&reg;;",
"     </li>",
"     <li>",
"      Mylan-Meloxicam;",
"     </li>",
"     <li>",
"      Novo-Meloxicam;",
"     </li>",
"     <li>",
"      PHL-Meloxicam;",
"     </li>",
"     <li>",
"      PMS-Meloxicam;",
"     </li>",
"     <li>",
"      ratio-Meloxicam;",
"     </li>",
"     <li>",
"      Teva-Meloxicam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"      see \"Meloxicam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time; adjust dose to specific patient&rsquo;s clinical needs. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 years: JIA: 0.125 mg/kg once daily; maximum dose: 7.5 mg/day; in clinical trials, higher doses (up to 0.375 mg/kg/day) did not demonstrate additional benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Osteoarthritis, rheumatoid arthritis: Initial: 7.5 mg once daily; some patients may receive additional benefit from an increased dose of 15 mg once daily; maximum dose: 15 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Significant impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Patients with severe renal impairment have not been adequately studied; use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Adults: Maximum dose: 7.5 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Additional doses are not required after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic dysfunction: No dosage adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: Patients with severe hepatic impairment have not been adequately studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 7.5 mg/5 mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mobic&reg;: 7.5 mg/5 mL (100 mL) [contains sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 7.5 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mobic&reg;: 7.5 mg, 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes:",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088646.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088646.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11340277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without meals; administer with food or milk to minimize gastrointestinal irritation. Oral suspension: Shake gently prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1023701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F) in tightly closed container; excursions permitted 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of signs and symptoms of pauciarticular or polyarticular juvenile idiopathic arthritis (JIA) (FDA approved in ages &ge;2 years); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14080490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, flatulence, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Falls, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal dreams, abnormal vision, agranulocytosis, albuminuria, allergic reaction, alopecia, anaphylactoid reactions, angina, angioedema, anxiety, appetite increased, arrhythmia, asthma, bilirubinemia, bronchospasm, bullous eruption, BUN increased, cardiac failure, colitis, confusion, conjunctivitis, creatinine increased, dehydration, depression, diaphoresis, duodenal perforation, duodenal ulcer, dyspnea, edema (facial), eructation, erythema multiforme, esophagitis, exfoliative dermatitis, fatigue, fever, gastric perforation, gastric ulcer, gastritis, gastroesophageal reflux, gastrointestinal hemorrhage, GGT increased, hematemesis, hematuria, hepatic failure, hepatitis, hot flushes, hyper-/hypotension, interstitial nephritis, intestinal perforation, jaundice, leukopenia, malaise, melena, MI, mood alterations, nervousness, palpitation, pancreatitis, paresthesia, photosensitivity reaction, pruritus, purpura, renal failure, seizure, shock, somnolence, Stevens-Johnson syndrome, syncope, tachycardia, taste perversion, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transaminases increased, tremor, ulcerative stomatitis, urinary retention (acute), urticaria, vasculitis, vertigo, xerostomia, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to meloxicam or any component; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F11285752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with decreased hepatic function; meloxicam is significantly metabolized in the liver; closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred. Use with caution in patients with asthma; asthmatic patients may have aspirin-sensitive asthma which may be associated with severe and potentially fatal bronchospasm when aspirin or NSAIDs are administered. Anemia (due to occult or gross blood loss from the GI tract, fluid retention, or other effect on erythropoiesis) may occur; monitor hemoglobin and hematocrit in patients receiving long term therapy. Use with caution and monitor carefully in patients with coagulation disorders or those receiving anticoagulants; NSAIDs inhibit platelet aggregation and may prolong bleeding time. Pediatric patients &ge; 2 years may experience a higher frequency of some adverse effects than adults, including the following:  Abdominal pain, diarrhea, fever, headache, and vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1023686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin's cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral use of NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, and in those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the \"aspirin triad\" who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy (beginning at 30 weeks gestation) as they may cause premature closure of the ductus arteriosus. NSAIDs may mask fever and inflammation and thus decrease the ability of these signs to help diagnose infectious conditions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cases of drug-induced hepatotoxicity (rare), including jaundice, hepatic failure resulting in death or requiring transplantation, have been reported. In up to 15% of patients taking NSAIDS, including meloxicam, elevations of one or more liver function tests may occur. Discontinue therapy immediately if abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, eosinophilia, rash, abdominal pain, diarrhea, dark urine).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; avoid use of meloxicam products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Oral suspension formulation may contain sorbitol. Concomitant use with sodium polystyrene sulfonate (Kayexalate&reg;) may cause intestinal necrosis (including fatal cases); combined use should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F191921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Meloxicam may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Meloxicam may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Meloxicam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1023700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of capsules following a high-fat meal resulted in a ~22% increase of mean peak serum drug concentration (C",
"     <sub>",
"      max",
"     </sub>",
"     ); the AUC was unchanged. With administration of suspension following a high-fat meal, neither C",
"     <sub>",
"      max",
"     </sub>",
"     nor AUC were affected.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C /D &ge;30 weeks gestation (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies meloxicam as pregnancy category C (category D: &ge;30 weeks gestation). Meloxicam crosses the placenta. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Product labeling for Mobic&reg; specifically notes that use at &ge;30 weeks gestation should be avoided and therefore classifies meloxicam as pregnancy category D at this time. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1023718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC, liver enzymes, serum BUN and creatinine, signs and symptoms of GI bleeding",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1023703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1023705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years (n=7): Apparent V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.19 L/kg (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 7-16 years (n=11): Apparent V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.13 L/kg (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Vd",
"     <sub>",
"      ss",
"     </sub>",
"     : 10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~99.4% bound, primarily albumin;",
"     <b>",
"      Note:",
"     </b>",
"     Free fraction was higher in adult patients with renal failure who were receiving chronic dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via CYP2C9 and CYP3A4 (minor); significant biliary and or enteral secretion occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 89%; suspension is bioequivalent to tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years (n=7): 13.4 hours (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 7-16 years (n=11): 12.7 hours (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Mean: 15-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 2-16 years (n=18): Suspension: Initial: 1-3 hours; secondary: 6-12 hours (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial: 4-5 hours; secondary: 12-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine and feces (as inactive metabolites); &lt;1% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-6 years (n=7): 0.17 mL/minute/kg (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 7-16 years (n=11): 0.12 mL/minute/kg (Burgos-Vargas, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 7-9 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1023722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/50/26405?source=see_link\">",
"      see \"Meloxicam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of meloxicam.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Meloxicam may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Protect skin from sun; use sunscreen, wide-brimmed hats, etc.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if changes in vision occur, if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; or palpitations. Report weight gain or swelling to physician.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burgos-Vargas R, Foeldvari I, Thon A, et al, \"Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid Arthritis,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2004, 44(8):866-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/18/2344/abstract-text/15286090/pubmed\" id=\"15286090\" target=\"_blank\">",
"        15286090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruperto N, Nikishina I, Pachanov ED, et al, \"A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis: Short- and Long-Term Efficacy and Safety Results,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2005, 52(2):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/18/2344/abstract-text/15692986/pubmed\" id=\"15692986\" target=\"_blank\">",
"        15692986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16017 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2344=[""].join("\n");
var outline_f2_18_2344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709031\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023678\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023712\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191849\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874886\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11340277\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023701\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023679\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080490\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191932\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023685\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11285752\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023686\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191921\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191858\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023700\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191860\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023718\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023703\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023705\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023722\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=related_link\">",
"      Meloxicam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/50/26405?source=related_link\">",
"      Meloxicam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_18_2345="Levator ani nerve";
var content_f2_18_2345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Female levator ani nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2345=[""].join("\n");
var outline_f2_18_2345=null;
var title_f2_18_2346="Benign lesions of the esophagus";
var content_f2_18_2346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Benign lesions of the esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/18/2346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/18/2346/contributors\">",
"     Daniel Wild, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/18/2346/contributors\">",
"     Moises Guelrud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/18/2346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/18/2346/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/18/2346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/18/2346/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/18/2346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of benign esophageal lesions are encountered during endoscopic or radiologic evaluation of the esophagus. Many are uncommon, cause no symptoms, and have no malignant potential. Nevertheless, they can pose a challenge in establishing an accurate diagnosis and thereby formulating a management plan. Benign esophageal lesions can be classified as raised, flat, or cystic.",
"   </p>",
"   <p>",
"    This topic will review many of the benign lesions that may be found in the esophagus. Esophageal strictures, Barrett's esophagus, and esophageal cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RAISED LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastrointestinal stromal tumors, leiomyomas, and leoimyosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lymphangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphangiomas are benign lesions that are believed to result from malformations of sequestered lymphatic tissue. They are most commonly found on the skin, but have been described everywhere in the body except the brain. There are fewer than 15 reported cases of esophageal lymphangiomas, almost all which of were diagnosed in children younger than two [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On endoscopy, they appear as a translucent, yellowish, easily compressible mass that is usually less than 5 mm. Standard endoscopic biopsies are often normal or show nonspecific esophagitis since the lesions are submucosal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Histologic examination of resection specimens reveals dilated endothelial spaces with cavities lined by flat endothelial cells containing eosinophilic material [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis can be suggested on endoscopic ultrasound (EUS) in which the lesion is solid and is located in the submucosal layer of the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/1\">",
"     1",
"    </a>",
"    ] and confirmed with tunneled biopsies.",
"   </p>",
"   <p>",
"    Conservative management is generally appropriate. However, on occasion, these lesions can grow and reach sizes up to 4 to 5 cm, in which case resection is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Although data are scarce, we perform band-assisted mucosectomy and endoscopic submucosal dissection for completely removing these lesions. Excision using a CO",
"    <sub>",
"     2",
"    </sub>",
"    laser has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal hemangiomas are rare; their prevalence in the general population was 0.04 percent based upon an autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority are cavernous (ie, have cavernous vascular spaces seen histologically), although capillary lesions have been described.",
"   </p>",
"   <p>",
"    Though usually solitary, multiple lesions can be seen in Osler-Weber-Rendu disease, Klippel-Tr&eacute;naunay syndrome, or congenital blue rubber bleb nevus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On endoscopy, they appear nodular, soft, bluish-red, and typically blanch when pressed with biopsy forceps. They must be differentiated from Kaposi's sarcoma, which may have a similar endoscopic appearance. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=see_link&amp;anchor=H4#H4\">",
"     \"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment\", section on 'Extracutaneous involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal hemangiomas are usually found incidentally. When symptomatic, they have most often been associated with bleeding and dysphagia. In such cases surgical resection has traditionally been performed but endoscopic resection has also been accomplished safely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fibrovascular polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrovascular polyps refer to a variety of lesions including fibromas, fibrolipomas, myomas, and lipomas that are differentiated by their histologic appearance. They contain a mixture of fibrous, vascular, and adipose tissue covered by squamous epithelium. They are rare, accounting for 0.5 to 1 percent of all benign esophageal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/8\">",
"     8",
"    </a>",
"    ]. They are most commonly encountered in the upper third of the esophagus and typically attach directly to the inferior aspect of the cricopharyngeus. About 75 percent of cases have been reported in men, for reasons that are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/9\">",
"     9",
"    </a>",
"    ]. Most have been in their fifties or sixties.",
"   </p>",
"   <p>",
"    Their pathogenesis is incompletely understood, but they likely arise from nodular thickening of a redundant mucosal fold. Such areas can elongate as the result of propulsive forces during repeated swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibrovascular polyps do not generally cause symptoms. However, case reports have described prolapse of large lesions into the larynx causing asphyxiation; lesions as large as 20 cm have been reported (",
"    <a class=\"graphic graphic_picture graphicRef70481 \" href=\"UTD.htm?3/30/3557\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Other symptoms associated with large lesions include dysphagia, chronic cough, nausea, and vomiting. Polyps that extend into the proximal stomach are exposed to an acidic environment, which can lead to ulceration and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic polyps often have a stalk, permitting them to be removed endoscopically using a snare. We agree with other authors that EUS should be performed before excision to rule out the presence of a large vessel feeding the stalk of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/9\">",
"     9",
"    </a>",
"    ]. Endoscopic resection can be technically difficult when the stalk is attached to the proximal esophagus. Surgical resection may be required if a large feeding vessel is present or if the base of the stalk is endoscopically inaccessible. In the case of a large feeding vessel, endoscopic resection may still be possible with use of an Endoloop placed on the stalk of the polyp before polypectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=see_link&amp;anchor=H12#H12\">",
"     \"Bleeding after colonic polypectomy\", section on 'Detachable loops'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Granular cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granular cell tumors occur in the skin, tongue, breast, and gastrointestinal tract. Approximately 10 percent arise in the gastrointestinal tract, most commonly in the esophagus, which is involved in up to 65 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/12\">",
"     12",
"    </a>",
"    ]. Nevertheless, granular cell tumors of the esophagus are rare; their incidence in endoscopy series has been estimated to be approximately 0.033 percent, representing about 1 percent of benign esophageal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=see_link\">",
"     \"Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mean age at diagnosis is 45 years and 60 percent of reported patients have been men [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/12\">",
"     12",
"    </a>",
"    ]. Up to one-third of patients with granular cell tumors of the esophagus report dysphagia; the others are mainly asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On endoscopy, these lesions are typically sessile, yellowish-white, and are covered by normal-appearing mucosa. They feel firm or rubbery when prodded with a biopsy forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/15\">",
"     15",
"    </a>",
"    ]. Most patients have solitary lesions but up to 10 percent have two or more lesions at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, granular cell tumors are composed of large polygonal cells containing numerous eosinophilic granules. In one patient, the diagnosis of granular cell tumors preceded the diagnosis of eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. They resemble Schwann cells under electron microscopy and stain positive for S100 protein, suggesting that they originate from cells of neural origin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard cold biopsy forceps provided adequate tissue to reach a diagnosis in most reported cases. However, we advocate tunneled biopsies because superficial biopsies may be normal or can miss the diagnosis, showing only fragments of normal squamous mucosa or revealing hyperplastic changes that can be confused with squamous cell carcinoma, potentially leading to misdiagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike most of the other esophageal lesions discussed in this topic review, granular cell tumors have malignant potential. Malignancy is more likely with large lesions and those that exhibit growth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/18\">",
"     18",
"    </a>",
"    ]. In a review of 183 cases, eight lesions (4 percent) were malignant; all of these lesions were greater than 4 cm and had histological features of infiltrative growth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/12\">",
"     12",
"    </a>",
"    ]. They have also been synchronously diagnosed with esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rare, because there is malignant potential, we suggest endoscopic resection of all granular cell tumors. Smaller lesions can be removed with a biopsy forceps but lesions larger than 1 cm may require endoscopic mucosal resection. Recurrence after resection has not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal adenomas arise almost exclusively in segments of Barrett's esophagus and likely represent a polypoid or nodular form of dysplasia rather than an isolated polypoid adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/20\">",
"     20",
"    </a>",
"    ]. Adenomas occurring in the absence of Barrett's esophagus have been described only in older case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/21\">",
"     21",
"    </a>",
"    ]. The association with Barrett's esophagus is further supported by the concomitant finding of esophageal adenocarcinoma in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions as large as 1.5 cm have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/24\">",
"     24",
"    </a>",
"    ]. Multiple lesions giving the appearance of esophageal polyposis have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited experience to guide management of esophageal adenomas. If an adenoma-like lesion is apparent, we suggest carefully inspecting the adjacent mucosa to evaluate for areas of Barrett's mucosa. Enhanced endoscopic techniques such as narrow band imaging or chromoendoscopy can be considered in these cases. Even if not apparent endoscopically, we would suggest biopsying surrounding mucosa to evaluate for intestinal metaplasia. If Barrett's is confirmed, then we would advocate management similar to that used for nodular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysplastic Barrett's. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of Barrett's esophagus\", section on 'Treatment of high-grade dysplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the lesion is an isolated adenoma, without associated Barrett's, we advocate using a strategy similar to that used for colonic adenomas; lesions smaller than 1 cm should be resected endoscopically using a biopsy forceps or snare. Lesions larger than 1 cm and those containing high-grade dysplasia can be removed using endoscopic mucosal resection, whereas more advanced lesions may require surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inflammatory fibroid polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like fibrovascular polyps, inflammatory fibroid polyps describe a variety of lesions that are composed of reparative tissue with reactive blood vessels, fibroblasts, and inflammatory cells. They include hamartomas, inflammatory pseudopolyps, and eosinophilic granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    They are rare, with only one case found in 330,000 surgical specimens submitted in one hospital over 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/25\">",
"     25",
"    </a>",
"    ]. They are more commonly found in the stomach, small bowel, and colon than the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Their pathogenesis is unclear, but they are thought to occur primarily from acid reflux-induced inflammation, a theory supported by their occurrence mainly in the distal esophagus, including the gastroesophageal junction.",
"   </p>",
"   <p>",
"    Inflammatory fibroid polyps are considered to be benign, reactive inflammatory lesions whose defining histologic features include a connective tissue stroma and a diffuse eosinophilic infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/27\">",
"     27",
"    </a>",
"    ]. They generally are an incidental finding but can occasionally cause hemorrhage or dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/27\">",
"     27",
"    </a>",
"    ]. Rapid growth (to as large as 9 cm) has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A standard biopsy generally provides enough tissue to make a diagnosis. Resection is not necessary except for lesions that cause symptoms, which may warrant snare polypectomy or surgical resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Papillomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal papillomas are benign epithelial lesions characterized histologically by fingerlike projections of tissue lined by an increased number of squamous cells and a core of connective tissue that contains small blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/28\">",
"     28",
"    </a>",
"    ]. They are rare; their incidence in patients undergoing upper endoscopy has ranged from 0.01 to 0.45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], while their prevalence in the general population based on autopsy series ranged from 0.006 to 0.04 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of esophageal papillomas is uncertain but two theories have been proposed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several lines of evidence support an underlying inflammatory condition. Approximately 70 percent of papillomas occur in the distal one-third of the esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/34\">",
"       34",
"      </a>",
"      ], and have been associated with documented reflux, esophagitis, or mucosal irritants such as nasogastric tubes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. In addition, several reports have linked bougie-assisted mechanical esophageal dilation with papillomas [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Furthermore, animal studies have shown that papillomas can be induced by caustic mucosal irritation with benzopyrene and nitrosamines [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is also evidence to support a role of human papilloma virus (HPV) in the formation of esophageal papillomas, although data are inconclusive. Studies from Italy and Hungary have documented HPV in 21 to 46 percent of esophageal papillomas [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/30,39\">",
"       30,39",
"      </a>",
"      ], while studies from the United States, Finland, and Poland identified HPV in fewer than 5 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. It is possible that the differences may be related to geographic variability in the frequency of oral HPV infection, but further studies are needed. A role for HPV is also supported by the observation that esophageal cases have been associated with serotypes 6 and 11 (strains commonly found in the human oropharynx and genital tract), implicating sexual transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      HPV has been unequivocally linked to cancer in the larynx and cervix, but its role in the pathogenesis of esophageal cancer remains unclear. HPV has been detected in esophageal squamous cell carcinoma, and there are descriptions of the simultaneous detection of squamous cell carcinoma and papillomas [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/30,39\">",
"       30,39",
"      </a>",
"      ]. However, there is limited direct evidence of malignant transformation related to HPV infection in the esophagus. A similar virus, bovine papilloma virus (BPV), has been linked to the malignant transformation of esophageal papillomas in cattle [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/27,44\">",
"       27,44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"       \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Esophageal papillomas have been most commonly diagnosed in patients who are in their 50s [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/34,36,45\">",
"     34,36,45",
"    </a>",
"    ]. Some studies suggest they are more common in men (male to female ratio of 1.8-3.4 in various reports) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/34,36,45\">",
"     34,36,45",
"    </a>",
"    ], while others have reported an equal sex distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of papillomas are solitary, although patients with over 10 lesions have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/36\">",
"     36",
"    </a>",
"    ]. On endoscopy, they appear as small, whitish-pink, wart-like exophytic projections (",
"    <a class=\"graphic graphic_picture graphicRef63177 \" href=\"UTD.htm?7/10/7343\">",
"     picture 2",
"    </a>",
"    ) that must be differentiated from other similar-appearing lesions, such as verrucous squamous cell carcinoma, granulation tissue, and papillary leukoplakia. They can be seen more frequently in patients with tylosis and acanthosis nigricans and there is an association with Goltz syndrome, a congenital disorder of focal dermal hypoplasia that features hyperpigmentation, sclerodactyly, dysplastic changes of the teeth and bones, and perianal, oroesophageal, and genital papillomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most lesions do not cause symptoms, but large lesions can cause dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/36,47\">",
"     36,47",
"    </a>",
"    ]. Papillomas are generally amenable to endoscopic resection. Lesions smaller than 1 cm can usually be removed with a cold-forceps biopsy, but larger lesions require endoscopic mucosal resection. Recurrence after resection is infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FLAT LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heterotopic sebaceous glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterotopic sebaceous glands are generally found in tissues of ectodermal origin such as the external genitalia, parotid gland, palms and soles, eyelashes and lips, and mouth and tongue (where they are known as Fordyce spots). They are rare in tissues of endodermal origin such as the esophagus.",
"   </p>",
"   <p>",
"    The pathogenesis of esophageal heterotopic sebaceous glands is unclear. They were not found in a large autopsy series of infants and children, suggesting that they are unlikely to be congenital [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/48\">",
"     48",
"    </a>",
"    ]. One theory is that they result from reactive metaplasia of ectopic, pluripotent salivary type mucous glands in the esophagus that were displaced during embryonic development [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the observation that the number and size of these lesions do not change with time suggest that they result from heterotopic (aberrantly placed) mucosa and not metaplastic change [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On endoscopy, the glands appear as yellowish-gray, plaque-like lesions that resemble xanthelasmas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. They frequently occur in clusters, with several cases of up to 100 lesions reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. Microscopically, the lesions show lobules of cells with sebaceous differentiation within the lamina propria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/51\">",
"     51",
"    </a>",
"    ]. Microscopic foci of nonspecific inflammation have occasionally been described adjacent to the sebaceous lobules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic review of standard cold biopsies is generally sufficient to make the diagnosis. Surveillance or resection is not required since there is no known malignant potential [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Glycogen acanthosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen acanthosis has been described in the esophagus on 3.5 to 15 percent of all upper endoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and in up to 30 percent of patients getting double contrast esophageal imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/56\">",
"     56",
"    </a>",
"    ]. It typically appears as multiple, uniformly sized round elevations in otherwise normal-appearing mucosa, usually in the midportion of the esophagus (",
"    <a class=\"graphic graphic_picture graphicRef56274 \" href=\"UTD.htm?33/57/34718\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/54\">",
"     54",
"    </a>",
"    ]. They are typically 2 to 10 mm in diameter, but lesions up to 15 mm have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis is unclear; they have no relation to glucose metabolism, diabetes, or the presence of acanthosis nigricans. Esophageal glycogen acanthosis has been described in association with Cowden disease, a rare autosomal dominant disease manifested by multiple hamartomas frequently involving the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. There is also some evidence to suggest an association with celiac disease, especially in children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H232666195#H232666195\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Esophageal glycogen acanthosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients have been diagnosed in their forties and fifties and, for unclear reasons, most are men [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/55\">",
"     55",
"    </a>",
"    ]. The lesions are believed to grow more numerous and larger with age but do not cause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis can be established by mucosal biopsies with standard cold forceps, which show multifocal plaques of hyperplastic squamous epithelium with abundant intracellular glycogen (",
"    <a class=\"graphic graphic_picture graphicRef67987 \" href=\"UTD.htm?15/40/16001\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/57\">",
"     57",
"    </a>",
"    ]. However, biopsies are rarely needed since the visual findings on endoscopy are highly predictive when the lesions have been confirmed histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/55\">",
"     55",
"    </a>",
"    ]. Further confirmation can be achieved by application of Lugol's solution, which turns the glycogen-containing plaques dark brown, thereby distinguishing glycogenic acanthosis from leukoplakia, moniliasis, and bullous pemphigoid, all of which can have a similar endoscopic appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inlet patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;An esophageal inlet patch (also referred to as heterotopic gastric mucosa of the upper esophagus [HGMUE]) consists of a discreet area resembling gastric mucosa that is typically found in the proximal esophagus. The prevalence of the inlet patch in the general population approached 5 percent in an autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/48\">",
"     48",
"    </a>",
"    ], while endoscopic studies have reported it to be present in 0.4 to 11 percent of patients undergoing diagnostic upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/61-68\">",
"     61-68",
"    </a>",
"    ]. The lower prevalence in endoscopic studies may be due to the proximal location of inlet patches. They are most commonly found in the proximal 3 cm of the esophagus, usually just distal to the upper esophageal sphincter, an area that is not always seen well during routine upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/61,63,65\">",
"     61,63,65",
"    </a>",
"    ]. Inlet patches have been described in people of all ages, but the most common age of detection is in the mid fifties [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the esophageal inlet patch is not known precisely. The term \"heterotopic\" gastric mucosa, sometimes used to describe it, may be a misnomer since some evidence suggests that the patch is composed of embryonic (rather than heterotopic) gastric mucosa. Immunohistochemical analysis has shown that the patch contains glucagon reactive cells that are not found in the mature human stomach, but are seen in its embryonic form [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, the patch is frequently discovered in children and its prevalence does not increase with age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One hypothesis is that the columnar lining of the esophagus in the embryo is not completely replaced by pseudostratified squamous epithelium during fetal development [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/70\">",
"     70",
"    </a>",
"    ]. However, conflicting data have also been published. Some studies based on immunohistochemical analysis found that inlet patches more closely resemble Barrett's mucosa, an acquired lesion, rather than normal gastric mucosa, making a congenital origin seem less likely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several authors have advanced a \"mixed theory,\" suggesting that the patch occurs as the result of a loss of normal squamous epithelium (from trauma, regurgitation, or infection) and subsequent healing by surfacing ectopic gastric mucosa present in the underlying lamina propria as the result of a congenital anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patches range in size from 2 mm to 4.5 cm and can be solitary or multiple [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. They are usually red, velvety, and flat (",
"    <a class=\"graphic graphic_picture graphicRef57315 \" href=\"UTD.htm?36/19/37169\">",
"     picture 5",
"    </a>",
"    ), although raised polypoid patches have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies reveal corpus or fundic-type gastric mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/61,63,64,66\">",
"     61,63,64,66",
"    </a>",
"    ], sometimes with parietal cells capable of secreting acid [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/67,75,76\">",
"     67,75,76",
"    </a>",
"    ]. Microscopically, inlet patches also commonly have an associated inflammatory infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most inlet patches are found incidentally and do not cause symptoms. In a prospective study, an inlet patch was found in 11 percent of the 300 studied patients, but there was no association between the presence of an inlet patch and the reported severity of pyrosis, hoarseness, or dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/68\">",
"     68",
"    </a>",
"    ]. However, a wide range of clinical sequelae have been attributed to inlet patches, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perforation and a tracheoesophageal fistula occurring at the site of an inlet patch [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. The presumed mechanism is related to acid production by the patch.",
"     </li>",
"     <li>",
"      Dysphagia, commonly from strictures, rings, and webs associated with the patch [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/79-81\">",
"       79-81",
"      </a>",
"      ]. The association with webs and the potential for acid production and ulceration has led some authors to propose that the inlet patch is a possible underlying etiology for Plummer-Vinson syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=see_link\">",
"       \"Esophageal webs and rings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interestingly, Helicobacter pylori can be localized in the patch in 19 to 73 percent of patients who are colonized in the stomach, raising the possibility that it acts as a reservoir for oral-oral transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/64,83,84\">",
"       64,83,84",
"      </a>",
"      ]. In a study with 68 patients with inlet patches, H. pylori was detected in 23 percent, all of whom reported globus sensation, suggesting a possible correlation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/85\">",
"       85",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=see_link\">",
"       \"Globus sensation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some studies have found that up to 20 percent of patients with an inlet patch have concomitant Barrett's esophagus in the distal esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/66\">",
"       66",
"      </a>",
"      ], but others have not confirmed such a correlation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are numerous reports of esophageal adenocarcinoma arising from an inlet patch in the upper esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/86-88\">",
"       86-88",
"      </a>",
"      ]. Additionally, there is one report of laryngeal adenocarcinoma diagnosed in a 22-year-old with an inlet patch [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An association with globus sensation, chronic cough, and laryngopharyngeal reflux has been suggested in various reports [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/90-93\">",
"       90-93",
"      </a>",
"      ]. A small randomized, sham-controlled trial found improvement in globus symptoms after ablation of the patch with argon plasma coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/94\">",
"       94",
"      </a>",
"      ]. Thus, it may be reasonable to look for inlet patches in these patients and, if found, attempt ablation with argon plasma coagulation, multipolar electrocoagulation, or radiofrequency ablation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=see_link\">",
"       \"Globus sensation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis can usually be made based upon visual inspection alone. Biopsies can be obtained if there is doubt about the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most inlet patches are found incidentally and do not cause symptoms. Thus, treatment is generally required only if complications develop.",
"   </p>",
"   <p>",
"    Specific risk factors for malignancy are unclear. As a result, consensus has not been achieved on surveillance. We do not perform surveillance endoscopy. There is limited evidence that endoscopic ablation followed by chronic proton pump inhibitor therapy can result in replacement of the inlet patch with normal squamous mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/81,94\">",
"     81,94",
"    </a>",
"    ]. The role of ablation remains unclear and we do not use this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Parakeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal parakeratosis appears endoscopically as whitish, membranous, linear plaques (",
"    <a class=\"graphic graphic_picture graphicRef70116 \" href=\"UTD.htm?16/3/16433\">",
"     picture 6",
"    </a>",
"    ) that do not stain (turn brown) when sprayed with Lugol's solution [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Biopsies reveal epithelial acanthosis, basal hyperplasia, and a dense, compact layer of parakeratosis, often featuring cytoplasmic eosinophilia and pyknotic nuclei, covered by an outer layer of nonnucleated squamous cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of esophageal parakeratosis is unclear; associations with esophageal and head and neck carcinoma have been reported but there is no evidence to suggest that areas of parakeratosis can themselves become neoplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. As an example, a prospective study of 400 patients with newly diagnosed squamous cell cancers of the head and neck found that close to 40 percent of patients had esophageal parakeratosis but none of the cancers clearly arose from such areas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/97\">",
"     97",
"    </a>",
"    ]. Another report described an association with submucosal fibrosis of the oral cavity, particularly in smokers and those who chewed betel nuts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/98\">",
"     98",
"    </a>",
"    ]. Because of the association with squamous cell cancer, we suggest careful evaluation of the esophagus and head and neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Esophagitis dissecans superficialis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagitis dissecans superficialis is a rare lesion characterized by sloughing of the entire length of esophageal mucosal epithelium (",
"    <a class=\"graphic graphic_picture graphicRef68821 \" href=\"UTD.htm?39/35/40499\">",
"     picture 7",
"    </a>",
"    ). The sloughed mucosal lining usually appears as a tubular cast within or tethered to the esophageal lumen (",
"    <a class=\"graphic graphic_picture graphicRef78182 \" href=\"UTD.htm?18/5/18515\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82733 \" href=\"UTD.htm?19/23/19826\">",
"     picture 9",
"    </a>",
"    ). It is most commonly seen in association with desquamating dermatologic disorders, particularly Pemphigus vulgaris, where it has been described in up to 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. It has also been described as a complication of rigid endoscopy with esophageal dilation, ingestion of oral bisphosphonates, and celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. We have seen it following the accidental ingestion of a fish bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CYSTIC LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Bronchiogenic and enterogenous cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic lesions of the esophagus were present in 1 in 8200 patients based upon review of four autopsy studies that included a total of close to 50,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ]. Most esophageal cysts arise from mediastinal structures (ie, bronchiogenic or enterogenic), although there have been a few case reports of esophageal teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchiogenic and enterogenic cysts are distinguished mainly by content and lining of the cysts. Bronchogenic cysts contain milky white material and are lined by columnar epithelium containing smooth muscle, hyaline cartilage, or a focus of seromucous glands, while enterogenous cysts are filled with greenish mucous and are lined with intestinal or gastric epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both types of cysts form as the result of abnormal budding of the primitive tracheobronchial tree. They can be periesophageal, but are more commonly intrapulmonary or found in the mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ]. Their average size is 4 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On endoscopy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies, the cysts appear as a protruding, submucosal mass covered by normal mucosa. If suspected based upon these studies, EUS can confirm the diagnosis. Because there is no clinical relevance to differentiating these two types of cysts, we do not advocate obtaining a fine-needle aspiration biopsy, especially since it can cause infection of the cysts or bleeding.",
"   </p>",
"   <p>",
"    Large cysts can cause dysphagia, which generally requires surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/107\">",
"     107",
"    </a>",
"    ]. Neither of these cysts has been reported to harbor neoplastic change and thus no treatment or surveillance is necessary in patients who are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Esophageal duplication/duplication cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplication cysts are congenital anomalies that arise during early embryonic development. They are most frequently found in the proximal small intestine, although they can also be found in the esophagus, stomach, and colon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=see_link\">",
"     \"Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duplication cysts of the esophagus have been estimated to occur in 1 out of 8000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ]. They are defined by three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They lay within the esophageal wall",
"     </li>",
"     <li>",
"      They are covered by two muscle layers",
"     </li>",
"     <li>",
"      They contain squamous epithelium or a lining compatible with that found in the embryonic esophagus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Up to one-third of these cysts contain heterotopic gastric mucosa and they can also contain heterotopic pancreatic mucosa or mucosa consistent with Peyer's patches [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 80 percent of cysts do not communicate with the esophageal lumen; the others generally run parallel to and communicate with the esophageal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ]. They most commonly occur on the right lateral aspect of the esophagus due to the dextrorotation of the stomach during embryogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal duplication cysts frequently cause symptoms, unlike duplication cysts in other parts of the gastrointestinal tract. As a result, about 80 percent are diagnosed before the age of 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/108\">",
"     108",
"    </a>",
"    ]. Because of compression of adjacent structures, they most commonly cause dysphagia (70 percent), epigastric pain (20 percent), retrosternal pain (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"     104",
"    </a>",
"    ], and respiratory symptoms including cough, stridor, and wheezing. Hematemesis has also been reported in a patient with a communicating, tubular duplication [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/110\">",
"     110",
"    </a>",
"    ]. Surgical resection is generally required for cysts that cause symptoms. Malignancy within these cysts is rare but has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/18/2346/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. Because of the low risk, we do not perform surveillance endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign esophageal lesions can be classified as raised, flat, or cystic. Most can be diagnosed based upon their endoscopic appearance, findings on routine biopsy and, in the case of submucosal lesions, by endoscopic ultrasound.",
"     </li>",
"     <li>",
"      Management is generally based upon the confidence in the diagnosis and whether the lesion is causing symptoms. However, a few of the lesions have the potential to progress to malignancy or may be a marker for an increased risk of malignancy, while not directly having malignant potential. Our approach to such lesions is summarized below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Esophageal parakeratosis has been associated with esophageal and head-and-neck carcinoma. As a result, we suggest careful examination of the esophagus and refer patients to an otolaryngologist for examination of the mouth and pharyngeal structures. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Parakeratosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal papillomas have been associated with esophageal squamous cell carcinoma in some reports. As a result, we suggest removing these lesions endoscopically. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Papillomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal adenomas are almost always found in areas of Barrett's esophagus. Thus, their management is usually based upon the management Barrett's esophagus with dysplasia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adenomas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"       \"Management of Barrett's esophagus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with granular cell tumors, we suggest endoscopic mucosal resection for lesions &ge;4 cm. For smaller lesions, we suggest surveillance endoscopy every one to two years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Granular cell tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of malignancy is probably too low to warrant surveillance or prophylactic measures for inlet patches and duplication cysts and thus we suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing surveillance in such patients. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Inlet patch'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Esophageal duplication/duplication cysts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/1\">",
"      Saers T, Parusel M, Brockmann M, Krakamp B. Lymphangioma of the esophagus. Gastrointest Endosc 2005; 62:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/2\">",
"      Yoshida Y, Okamura T, Ezaki T, et al. Lymphangioma of the oesophagus: a case report and review of the literature. Thorax 1994; 49:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/3\">",
"      Yoon YH, Kim KH, Baek WK, et al. Lymphangioma of the esophagus: surgical treatment. Ann Thorac Surg 2004; 78:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/4\">",
"      Best SR, Coelho DH, Ahrens WA, et al. Laser excision of multiple esophageal lymphangiomas: a case report and review of the literature. Auris Nasus Larynx 2008; 35:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/5\">",
"      Moersch HJ, Harrington SW. Benign tumor of the esophagus. Ann Otl Rhnol Laryngol 1944; 53:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/6\">",
"      Rasalkar DD, Chiu PW, Teoh AY, Chu WC. Oesophageal haemangioma: imaging characteristics of this rare condition. Hong Kong Med J 2010; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/7\">",
"      Sogabe M, Taniki T, Fukui Y, et al. A patient with esophageal hemangioma treated by endoscopic mucosal resection: a case report and review of the literature. J Med Invest 2006; 53:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/8\">",
"      Palanivelu C, Rangarajan M, John SJ, et al. A rare cause of intermittent dysphagia: giant fibrovascular polyp of the proximal esophagus. J Coll Physicians Surg Pak 2007; 17:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/9\">",
"      Avezzano EA, Fleischer DE, Merida MA, Anderson DL. Giant fibrovascular polyps of the esophagus. Am J Gastroenterol 1990; 85:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/10\">",
"      Owens JJ, Donovan DT, Alford EL, et al. Life-threatening presentations of fibrovascular esophageal and hypopharyngeal polyps. Ann Otol Rhinol Laryngol 1994; 103:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/11\">",
"      Patel J, Kieffer RW, Martin M, Avant GR. Giant fibrovascular polyp of the esophagus. Gastroenterology 1984; 87:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/12\">",
"      Orlowska J, Pachlewski J, Gugulski A, Butruk E. A conservative approach to granular cell tumors of the esophagus: four case reports and literature review. Am J Gastroenterol 1993; 88:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/13\">",
"      Franzin G, Capitanio A, Manfrini C, et al. Granular cell tumors of the oesophagus: report of 6 cases and review of literature. Ital J Gastroenterol 1982; 14:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/14\">",
"      Gershwind ME, Chiat H, Addei KA, Ferraro LR. Granular cell tumors of the esophagus. Gastrointest Radiol 1978; 2:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/15\">",
"      Brady PG, Nord HJ, Connar RG. Granular cell tumor of the esophagus: natural history, diagnosis, and therapy. Dig Dis Sci 1988; 33:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/16\">",
"      Lucendo AJ, De Rezende L, Mart&iacute;n-Plaza J, Larrauri J. Esophageal granular cell tumor and eosinophilic esophagitis: two interesting entities identified in the same patient. Case Rep Gastroenterol 2008; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/17\">",
"      Stefansson K, Wollmann RL. S-100 protein in granular cell tumors (granular cell myoblastomas). Cancer 1982; 49:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/18\">",
"      Vuyk HD, Snow GB, Tiwari RM, et al. Granular cell tumor of the proximal esophagus. A rare disease. Cancer 1985; 55:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/19\">",
"      Alkhoury F, Martin JT, Fiedler P, Jaffe PE. Esophageal granular cell tumor colliding with intramucosal adenocarcinoma: a case report. Cases J 2009; 2:8093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/20\">",
"      Lee RG. Adenomas arising in Barrett's esophagus. Am J Clin Pathol 1986; 85:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/21\">",
"      Spin FP. Adenomas of the esophagus: a case report and review of the literature. Gastrointest Endosc 1973; 20:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/22\">",
"      Wong RS, Temes RT, Follis FM, et al. Multiple polyposis and adenocarcinoma arising in Barrett's esophagus. Ann Thorac Surg 1996; 61:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/23\">",
"      Paraf F, Fl&eacute;jou JF, Potet F, et al. Adenomas arising in Barrett's esophagus with adenocarcinoma. Report of three cases. Pathol Res Pract 1992; 188:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/24\">",
"      Keeffe EB, Hisken EC, Schubert F. Adenomatous polyp arising in Barrett's esophagus. J Clin Gastroenterol 1986; 8:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/25\">",
"      LiVolsi VA, Perzin KH. Inflammatory pseudotumors (inflammatory fibrous polyps) of the esophagus. A clinicopathologic study. Am J Dig Dis 1975; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/26\">",
"      Stolte M, Sticht T, Eidt S, et al. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy 1994; 26:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/27\">",
"      Godey SK, Diggory RT. Inflammatory fibroid polyp of the oesophagus. World J Surg Oncol 2005; 3:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/28\">",
"      Kuwano H, Ueo H, Sugimachi K, et al. Glandular or mucus-secreting components in squamous cell carcinoma of the esophagus. Cancer 1985; 56:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/29\">",
"      Sablich R, Benedetti G, Bignucolo S, Serraino D. Squamous cell papilloma of the esophagus. Report on 35 endoscopic cases. Endoscopy 1988; 20:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/30\">",
"      Sz&aacute;nt&oacute; I, Szentirmay Z, Banai J, et al. [Squamous papilloma of the esophagus. Clinical and pathological observations based on 172 papillomas in 155 patients]. Orv Hetil 2005; 146:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/31\">",
"      Mosca S, Manes G, Monaco R, et al. Squamous papilloma of the esophagus: long-term follow up. J Gastroenterol Hepatol 2001; 16:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/32\">",
"      ADLER RH, CARBERRY DM, ROSS CA. Papilloma of the esophagus: association with hiatal hernia. J Thorac Surg 1959; 37:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/33\">",
"      PLACHTA A. Benign tumors of the esophagus. Review of literature and report of 99 cases. Am J Gastroenterol 1962; 38:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/34\">",
"      Quitadamo M, Benson J. Squamous papilloma of the esophagus: a case report and review of the literature. Am J Gastroenterol 1988; 83:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/35\">",
"      Fern&aacute;ndez-Rodr&iacute;guez CM, Badia-Figuerola N, Ruiz del Arbol L, et al. Squamous papilloma of the esophagus: report of six cases with long-term follow-up in four patients. Am J Gastroenterol 1986; 81:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/36\">",
"      Carr NJ, Monihan JM, Sobin LH. Squamous cell papilloma of the esophagus: a clinicopathologic and follow-up study of 25 cases. Am J Gastroenterol 1994; 89:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/37\">",
"      Nakamura T, Matsuyama M, Kishimoto H. Tumors of the esophagus and duodenum induced in mice by oral administration of N-ethyl-N'-nitro-N-nitrosoguanidine. J Natl Cancer Inst 1974; 52:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/38\">",
"      Dunham LJ, Sheets RH. Effects of esophageal constriction on benzo(alpha)pyrene carcinogenesis in hamster esophagus and forestomach. J Natl Cancer Inst 1974; 53:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/39\">",
"      Syrj&auml;nen KJ. HPV infections and oesophageal cancer. J Clin Pathol 2002; 55:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/40\">",
"      Chang F, Janatuinen E, Pikkarainen P, et al. Esophageal squamous cell papillomas. Failure to detect human papillomavirus DNA by in situ hybridization and polymerase chain reaction. Scand J Gastroenterol 1991; 26:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/41\">",
"      Carr NJ, Bratthauer GL, Lichy JH, et al. Squamous cell papillomas of the esophagus: a study of 23 lesions for human papillomavirus by in situ hybridization and the polymerase chain reaction. Hum Pathol 1994; 25:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/42\">",
"      Poljak M, Orlowska J, Cerar A. Human papillomavirus infection in esophageal squamous cell papillomas: a study of 29 lesions. Anticancer Res 1995; 15:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/43\">",
"      Politoske EJ. Squamous papilloma of the esophagus associated with the human papillomavirus. Gastroenterology 1992; 102:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/44\">",
"      Campo MS. Papillomas and cancer in cattle. Cancer Surv 1987; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/45\">",
"      Odze R, Antonioli D, Shocket D, et al. Esophageal squamous papillomas. A clinicopathologic study of 38 lesions and analysis for human papillomavirus by the polymerase chain reaction. Am J Surg Pathol 1993; 17:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/46\">",
"      Brinson RR, Schuman BM, Mills LR, et al. Multiple squamous papillomas of the esophagus associated with Goltz syndrome. Am J Gastroenterol 1987; 82:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/47\">",
"      Kostiainen S, Teppo L, Virkkula L. Papilloma of the oesophagus. Report of a case. Scand J Thorac Cardiovasc Surg 1973; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/48\">",
"      Rector LE, Connerley ML. Aberrant mucosa in esophagus in infants and in children. Arch Pathol 1941; 31:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/49\">",
"      Bertoni G, Sassatelli R, Nigrisoli E, et al. Ectopic sebaceous glands in the esophagus: report of three new cases and review of the literature. Am J Gastroenterol 1994; 89:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/50\">",
"      Marcial MA, Villafa&ntilde;a M. Esophageal ectopic sebaceous glands: endoscopic and histologic findings. Gastrointest Endosc 1994; 40:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/51\">",
"      Nakanishi Y, Ochiai A, Shimoda T, et al. Heterotopic sebaceous glands in the esophagus: histopathological and immunohistochemical study of a resected esophagus. Pathol Int 1999; 49:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/52\">",
"      Hoshika K, Inoue S, Mizuno M, et al. Endoscopic detection of ectopic multiple minute sebaceous glands in the esophagus. Report of a case and review of the literature. Dig Dis Sci 1995; 40:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/53\">",
"      Ramakrishnan T, Brinker JE. Ectopic sebaceous glands in the esophagus. Gastrointest Endosc 1978; 24:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/54\">",
"      Vadva MD, Triadafilopoulos G. Glycogenic acanthosis of the esophagus and gastroesophageal reflux. J Clin Gastroenterol 1993; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/55\">",
"      Stern Z, Sharon P, Ligumsky M, et al. Glycogenic acanthosis of the esophagus. A benign but confusing endoscopic lesion. Am J Gastroenterol 1980; 74:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/56\">",
"      Glick SN, Teplick SK, Goldstein J, et al. Glycogenic acanthosis of the esophagus. AJR Am J Roentgenol 1982; 139:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/57\">",
"      Ghahremani GG, Rushovich AM. Glycogenic acanthosis of the esophagus: radiographic and pathologic features. Gastrointest Radiol 1984; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/58\">",
"      McGarrity TJ, Wagner Baker MJ, Ruggiero FM, et al. GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations. Am J Gastroenterol 2003; 98:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/59\">",
"      Kay PS, Soetikno RM, Mindelzun R, Young HS. Diffuse esophageal glycogenic acanthosis: an endoscopic marker of Cowden's disease. Am J Gastroenterol 1997; 92:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/60\">",
"      Suoglu OD, Emiroglu HH, Sokucu S, et al. Celiac disease and glycogenic acanthosis: a new association? Acta Paediatr 2004; 93:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/61\">",
"      Borhan-Manesh F, Farnum JB. Incidence of heterotopic gastric mucosa in the upper oesophagus. Gut 1991; 32:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/62\">",
"      Jacobs E, Dehou MF. Heterotopic gastric mucosa in the upper esophagus: a prospective study of 33 cases and review of literature. Endoscopy 1997; 29:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/63\">",
"      Jabbari M, Goresky CA, Lough J, et al. The inlet patch: heterotopic gastric mucosa in the upper esophagus. Gastroenterology 1985; 89:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/64\">",
"      Akbayir N, Alkim C, Erdem L, et al. Heterotopic gastric mucosa in the cervical esophagus (inlet patch): endoscopic prevalence, histological and clinical characteristics. J Gastroenterol Hepatol 2004; 19:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/65\">",
"      Azar C, Jamali F, Tamim H, et al. Prevalence of endoscopically identified heterotopic gastric mucosa in the proximal esophagus: endoscopist dependent? J Clin Gastroenterol 2007; 41:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/66\">",
"      Tang P, McKinley MJ, Sporrer M, Kahn E. Inlet patch: prevalence, histologic type, and association with esophagitis, Barrett esophagus, and antritis. Arch Pathol Lab Med 2004; 128:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/67\">",
"      Nakajima H, Munakata A, Sasaki Y, Yoshida Y. pH profile of esophagus in patients with inlet patch of heterotopic gastric mucosa after tetragastrin stimulation. An endoscopic approach. Dig Dis Sci 1993; 38:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/68\">",
"      Weickert U, Wolf A, Schr&ouml;der C, et al. Frequency, histopathological findings, and clinical significance of cervical heterotopic gastric mucosa (gastric inlet patch): a prospective study in 300 patients. Dis Esophagus 2011; 24:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/69\">",
"      Feurle GE, Helmstaedter V, Buehring A, et al. Distinct immunohistochemical findings in columnar epithelium of esophageal inlet patch and of Barrett's esophagus. Dig Dis Sci 1990; 35:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/70\">",
"      JOHNS BA. Developmental changes in the oesophageal epithelium in man. J Anat 1952; 86:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/71\">",
"      Bogomoletz WV, Geboes K, Feydy P, et al. Mucin histochemistry of heterotopic gastric mucosa of the upper esophagus in adults: possible pathogenic implications. Hum Pathol 1988; 19:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/72\">",
"      DELAPAVA S, PICKREN JW, ADLER RH. ECTOPIC GASTRIC MUCOSA OF THE ESOPHAGUS. A STUDY ON HISTOGENESIS. N Y State J Med 1964; 64:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/73\">",
"      Rattner HM, McKinley MJ. Heterotopic gastric mucosa of the upper esophagus. Gastroenterology 1986; 90:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/74\">",
"      Shah KK, DeRidder PH, Shah KK. Ectopic gastric mucosa in proximal esophagus. Its clinical significance and hormonal profile. J Clin Gastroenterol 1986; 8:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/75\">",
"      Kim EA, Kang DH, Cho HS, et al. Acid secretion from a heterotopic gastric mucosa in the upper esophagus demonstrated by dual probe 24-hour ambulatory pH monitoring. Korean J Intern Med 2001; 16:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/76\">",
"      Raine CH. Ectopic gastric mucosa in the upper esophagus as a cause of dysphagia. Ann Otol Rhinol Laryngol 1983; 92:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/77\">",
"      Kohler B, K&ouml;hler G, Riemann JF. Spontaneous esophagotracheal fistula resulting from ulcer in heterotopic gastric mucosa. Gastroenterology 1988; 95:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/78\">",
"      S&aacute;nchez-Pernaute A, Hernando F, D&iacute;ez-Valladares L, et al. Heterotopic gastric mucosa in the upper esophagus (\"inlet patch\"): a rare cause of esophageal perforation. Am J Gastroenterol 1999; 94:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/79\">",
"      Yarborough CS, McLane RC. Stricture related to an inlet patch of the esophagus. Am J Gastroenterol 1993; 88:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/80\">",
"      Jerome-Zapadka KM, Clarke MR, Sekas G. Recurrent upper esophageal webs in association with heterotopic gastric mucosa: case report and literature review. Am J Gastroenterol 1994; 89:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/81\">",
"      McBride MA, Vanagunas AA, Breshnahan JP, Barch DB. Combined endoscopic thermal electrocoagulation with high dose omeprazole therapy in complicated heterotopic gastric mucosa of the esophagus. Am J Gastroenterol 1995; 90:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/82\">",
"      Weaver GA. Upper esophageal web due to a ring formed by a squamocolumnar junction with ectopic gastric mucosa (another explanation of the Paterson-Kelly, Plummer-Vinson syndrome). Dig Dis Sci 1979; 24:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/83\">",
"      Gutierrez O, Akamatsu T, Cardona H, et al. Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch). Am J Gastroenterol 2003; 98:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/84\">",
"      Borhan-Manesh F, Farnum JB. Study of Helicobacter pylori colonization of patches of heterotopic gastric mucosa (HGM) at the upper esophagus. Dig Dis Sci 1993; 38:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/85\">",
"      Alagozlu H, Simsek Z, Unal S, et al. Is there an association between Helicobacter pylori in the inlet patch and globus sensation? World J Gastroenterol 2010; 16:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/86\">",
"      Abe T, Hosokawa M, Kusumi T, et al. Adenocarcinoma arising from ectopic gastric mucosa in the cervical esophagus. Am J Clin Oncol 2004; 27:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/87\">",
"      Christensen WN, Sternberg SS. Adenocarcinoma of the upper esophagus arising in ectopic gastric mucosa. Two case reports and review of the literature. Am J Surg Pathol 1987; 11:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/88\">",
"      Noguchi T, Takeno S, Takahashi Y, et al. Primary adenocarcinoma of the cervical esophagus arising from heterotopic gastric mucosa. J Gastroenterol 2001; 36:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/89\">",
"      Basseri B, Conklin JL, Mertens RB, et al. Heterotopic gastric mucosa (inlet patch) in a patient with laryngopharyngeal reflux (LPR) and laryngeal carcinoma: a case report and review of literature. Dis Esophagus 2009; 22:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/90\">",
"      Meining A, Bajbouj M, Preeg M, et al. Argon plasma ablation of gastric inlet patches in the cervical esophagus may alleviate globus sensation: a pilot trial. Endoscopy 2006; 38:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/91\">",
"      Silvers WS, Levine JS, Poole JA, et al. Inlet patch of gastric mucosa in upper esophagus causing chronic cough and vocal cord dysfunction. Ann Allergy Asthma Immunol 2006; 96:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/92\">",
"      Alaani A, Jassar P, Warfield AT, et al. Heterotopic gastric mucosa in the cervical oesophagus (inlet patch) and globus pharyngeus--an under-recognised association. J Laryngol Otol 2007; 121:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/93\">",
"      Akbayir N, S&ouml;kmen HM, Cali�� AB, et al. Heterotopic gastric mucosa in the cervical esophagus: could this play a role in the pathogenesis of laryngopharyngeal reflux in a subgroup of patients with posterior laryngitis? Scand J Gastroenterol 2005; 40:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/94\">",
"      Bajbouj M, Becker V, Eckel F, et al. Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations. Gastroenterology 2009; 137:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/95\">",
"      Guelrud M, Herrera I, Eggenfeld H. Compact parakeratosis of esophageal mucosa. Gastrointest Endosc 2000; 51:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/96\">",
"      Muto M, Hironaka S, Nakane M, et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 2002; 56:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/97\">",
"      Mandard AM, Marnay J, Gignoux M, et al. Cancer of the esophagus and associated lesions: detailed pathologic study of 100 esophagectomy specimens. Hum Pathol 1984; 15:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/98\">",
"      Misra SP, Misra V, Dwivedi M, Gupta SC. Oesophageal subepithelial fibrosis: an extension of oral submucosal fibrosis. Postgrad Med J 1998; 74:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/99\">",
"      Kaplan RP, Touloukian J, Ahmed AR, Newcomer VD. Esophagitis dissecans superficialis associated with pemphigus vulgaris. J Am Acad Dermatol 1981; 4:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/100\">",
"      Rao PN, Samarth A, Aurangabadkar SJ, et al. Study of upper gastrointestinal tract involvement in pemphigus by esophago-gastro-duodenoscopy. Indian J Dermatol Venereol Leprol 2006; 72:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/101\">",
"      Hokama A, Ihama Y, Nakamoto M, et al. Esophagitis dissecans superficialis associated with bisphosphonates. Endoscopy 2007; 39 Suppl 1:E91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/102\">",
"      Ramaswami G, Jain PK, Talati VR. Oesophagitis dissecans superficialis complicating repeated rigid oesophagoscopy and dilatation. J Laryngol Otol 2007; 121:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/103\">",
"      Hage-Nassar G, Rotterdam H, Frank D, Green PH. Esophagitis dissecans superficialis associated with celiac disease. Gastrointest Endosc 2003; 57:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/104\">",
"      Arbona JL, Fazzi JG, Mayoral J. Congenital esophageal cysts: case report and review of literature. Am J Gastroenterol 1984; 79:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/105\">",
"      Bernat M, Struty��ska-Karpi��ska M, Lewandowski A, et al. [Benign esophageal tumors]. Wiad Lek 1993; 46:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/106\">",
"      Vade A, Nolan J. Posterior mediastinal teratoma involving the esophagus. Gastrointest Radiol 1989; 14:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/107\">",
"      Kollias VD, Panagiotides HC, Kantidakis GH, Charonis CG. Intramural bronchogenic cyst of the oesophagus: a rare entity. Respiration 1998; 65:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/108\">",
"      Ildstad ST, Tollerud DJ, Weiss RG, et al. Duplications of the alimentary tract. Clinical characteristics, preferred treatment, and associated malformations. Ann Surg 1988; 208:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/109\">",
"      Uppal P, Kaur J, Agarwala S, et al. Communicating oesophageal duplication cyst with heterotopic pancreatic tissue - an unusual cause of recurrent pneumonia in an infant. Acta Paediatr 2010; 99:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/110\">",
"      Mourra N, Flejou JF, Arrive L. Clinical challenges and images in GI. Extrahepatic biliary cystadenoma with mesenchymal stroma. Gastroenterology 2008; 134:1295,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/111\">",
"      McGregor DH, Mills G, Boudet RA. Intramural squamous cell carcinoma of the esophagus. Cancer 1976; 37:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/112\">",
"      Singh S, Lal P, Sikora SS, Datta NR. Squamous cell carcinoma arising from a congenital duplication cyst of the esophagus in a young adult. Dis Esophagus 2001; 14:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/18/2346/abstract/113\">",
"      Butler CL, Fende M. Double esophagus with carcinoma in one. Arch Pathol 1950; 49:605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2253 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2346=[""].join("\n");
var outline_f2_18_2346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RAISED LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastrointestinal stromal tumors, leiomyomas, and leoimyosarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lymphangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fibrovascular polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Granular cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inflammatory fibroid polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Papillomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FLAT LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heterotopic sebaceous glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Glycogen acanthosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inlet patch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Parakeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Esophagitis dissecans superficialis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CYSTIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Bronchiogenic and enterogenous cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Esophageal duplication/duplication cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2253|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/30/3557\" title=\"picture 1\">",
"      Fibrovascular polyp intraop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/10/7343\" title=\"picture 2\">",
"      Endosc esophageal papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/57/34718\" title=\"picture 3\">",
"      Glycogen acanthosis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16001\" title=\"picture 4\">",
"      Glycogen acanthosis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/19/37169\" title=\"picture 5\">",
"      Esophageal inlet patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/3/16433\" title=\"picture 6\">",
"      Esophageal parakeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/35/40499\" title=\"picture 7\">",
"      Esoph superficial dissecans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/5/18515\" title=\"picture 8\">",
"      Esophageal cast tethered",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/23/19826\" title=\"picture 9\">",
"      Esoph endoscopic removal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11304?source=related_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=related_link\">",
"      Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=related_link\">",
"      Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=related_link\">",
"      Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=related_link\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_18_2347="Bronchoscopy in ICU";
var content_f2_18_2347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for bronchoscopy in an intensive care unit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Placement/change of endotracheal tube*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm position of endotracheal tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for chemical/thermal injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localization/therapy for broncho-pleural fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluation of upper airway at extubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate radiographic opacities (ie, ventilator-associated pneunonia)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Especially in setting of craniofacial trauma or cervical spine instability.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2347=[""].join("\n");
var outline_f2_18_2347=null;
var title_f2_18_2348="Screening adrenal indcidentaloma";
var content_f2_18_2348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of the patient with an incidentally discovered adrenal mass",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Suggestive Clinical Features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Laboratory Tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Pheochromocytoma",
"      </td>",
"      <td rowspan=\"5\">",
"       Hypertension, Paroxysmal Symptoms (eg, palpitation, diaphoresis, headache, pallor, tremor)",
"      </td>",
"      <td class=\"sublist1_start\">",
"       24-hr urine:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       fractionated metanephrines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       fractionated catecholamines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Blood:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       fractionated metanephrines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Cushing's syndrome (CS)",
"      </td>",
"      <td rowspan=\"4\">",
"       Central obesity, proximal muscle weakness, thin skin, supraclavicular fat pad, facial plethora",
"      </td>",
"      <td class=\"sublist1_start\">",
"       For patients with symptoms of CS:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       24-hr urinary free cortisol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       For patients lacking symptoms of CS:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1-mg overnight dexamethasone suppression test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Primary aldosteronism",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypertension, hypokalemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plasma aldosterone concentration Plasma renin activity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Adrenocortical carcinoma",
"      </td>",
"      <td rowspan=\"2\">",
"       Mass effect symptoms, symptoms related to excess glucocorticoid, mineralocorticoid, androgen, or estrogen secretion",
"      </td>",
"      <td>",
"       Serum dehydroepiandrosterone sulfate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Measures of clinically indicated steroid",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2348=[""].join("\n");
var outline_f2_18_2348=null;
var title_f2_18_2349="Vulvar abscess antibiotics";
var content_f2_18_2349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic therapy for vulvar abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Outpatient oral antibiotic therapy options for vulvar abscess*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole)",
"       </td>",
"       <td>",
"        1 to 2 double strength",
"        <sup>",
"         &bull;",
"        </sup>",
"        tablets twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         600 mg three times daily or 300 to 450 mg three times daily for mild uncomplicated",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"       <td>",
"        600 mg twice daily",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Inpatient intravenous antibiotic therapy options for severe vulvar abscess/infection",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vancomycin",
"       </td>",
"       <td>",
"        15 to 20 mg/kg/dose every 8 to 12 hours (maximum 2 grams per dose)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"       <td>",
"        600 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daptomycin",
"       </td>",
"       <td>",
"        4 mg/kg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Telavancin",
"       </td>",
"       <td>",
"        10 mg/kg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        600 mg three times daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     NOTE: &nbsp;Antimicrobial for management of Bartholin&rsquo;s gland abscess is covered separately.&nbsp; See &ldquo;Disorders of Bartholin&rsquo;s gland&rdquo; section &ldquo;management&rdquo;.",
"    </p>",
"    <div class=\"footnotes\">",
"     * Outpatient antibiotic therapy for vulvar abscess is recommended for 5 to 10 days.",
"     <br>",
"      <sup>",
"       &bull;&nbsp;",
"      </sup>",
"      One double-strength tablet is 160 mg trimethoprim and 800 mg sulfamethoxazole.",
"      <br>",
"       <sup>",
"        &Delta;",
"       </sup>",
"       For empiric coverage combined with later generation oral cephalosporin (eg, cefuroxime axetil or cefprozil) or oral fluoroquinolone. (See text).",
"       <br>",
"        <sup>",
"         &loz;",
"        </sup>",
"        Oral clindamycin is a reasonable choice for empiric&nbsp;coverage if local resistance is low.&nbsp;Data on parenteral use for MRSA are limited.&nbsp; See \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section \"clindamycin\".",
"        <br>",
"         <sup>",
"          &sect;",
"         </sup>",
"         Due to the likelihood of methicillin-resistant",
"         <em>",
"          Staphylococcus aureus",
"         </em>",
"         (MRSA) infection in vulvar abscesses, these medications should be used in addition to broad-spectrum parenteral antibiotics for 7 to 14 days depending on response.",
"         <br>",
"          <sup>",
"           &yen;",
"          </sup>",
"          For patients with renal insufficiency, serious infection or who are obese, adjust dosage for serum trough concentration of 15-20 mcg/mL. See \"Vancomycin dosing and serum concentration monitoring in adults\".",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2349=[""].join("\n");
var outline_f2_18_2349=null;
var title_f2_18_2350="Example of epinephrine infusion - pediatric 10 kg";
var content_f2_18_2350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of epinephrine infusion - pediatric 10 kg",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis for pediatric patient of 10 kg body weight for emergency/critical care units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        <p>",
"         Epinephrine 10 micrograms/mL (0.01 mg/mL)",
"        </p>",
"        <p>",
"         Add 1 mg (1000 micrograms) of epinephrine to 100 mL of 5 percent dextrose water (D5W).",
"         <br/>",
"         Resulting concentration is 10 micrograms per milliliter (mL).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        1.",
"        <strong>",
"         CHECK",
"        </strong>",
"        vial strength.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        2. To prepare epinephrine infusion for a final concentration of",
"        <strong>",
"         10",
"        </strong>",
"        micrograms per mL, dilute",
"        <strong>",
"         10 mL",
"        </strong>",
"        of",
"        <strong>",
"         0.1 mg/mL",
"        </strong>",
"        epinephrine (also labeled 1:10,000) in 100mL of D5W",
"        <strong>",
"         OR",
"        </strong>",
"        1 mL of 1 mg/mL epinephrine (also labeled 1:1000) in 100 mL of D5W.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        Infuse an initial dose of 0.1 micrograms per kg per minute using a programmable infusion pump and titrate as needed while continuously monitoring the patient's cardiac rhythm and blood pressure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Pediatric dose for 10 kg child",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        <p>",
"         Administration rate",
"        </p>",
"        <p>",
"         1 milligram epinephrine diluted in 100 mL D5W",
"        </p>",
"        <p>",
"         10 micrograms per milliliter",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"subtitle3\">",
"        Micrograms per kg per minute",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"12\">",
"        Multiply by patient weight (10 kg)",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms per minute",
"       </td>",
"       <td class=\"subtitle3\">",
"        mL per",
"        <em>",
"         minute",
"        </em>",
"        for 10 kg child",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"12\">",
"        Multiply by 60 minutes",
"       </td>",
"       <td class=\"subtitle3\">",
"        mL per",
"        <em>",
"         hour",
"        </em>",
"        for 10 kg child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.5",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.1",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         1",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.1",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         6",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.2",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0.2",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.3",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         3",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.3",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         18",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.4",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        0.4",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.5",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         5",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.5",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         30",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.6",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        0.6",
"       </td>",
"       <td class=\"centered\">",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.7",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         7",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.7",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         42",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.8",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        0.8",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.9",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         9",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.9",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         54",
"        </span>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <ul>",
"         <li>",
"          To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion and standard concentration(s)",
"         </li>",
"         <li>",
"          The above table is provided as an example; there are other acceptable concentrations",
"         </li>",
"         <li>",
"          <strong>",
"           Intravenous epinephrine, like all vasopressors,&nbsp;can cause&nbsp;life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered ONLY by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous&nbsp;non-invasive electronic monitoring of heart rate and blood pressure.",
"          </strong>",
"         </li>",
"         <li>",
"          Epinephrine is an ischemia causing agent and peripheral venous irritant. Monitor infusion site for extravasation. See Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine. Central line administration is preferred when available.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Unused diluted solutions should be discarded within 24 hours or less of preparation depending on local standards.",
"    </div>",
"    <div class=\"reference\">",
"     References: Gahart BL, Nazareno AR; Intravenous Medications 28th ed. Elsevier-Mosby &copy; 2012 St. Louis, MO; Lieberman P, et al. J Allergy Clin Immunol 2010; 126(3):477.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2350=[""].join("\n");
var outline_f2_18_2350=null;
var title_f2_18_2351="Abdominal pain diary PI";
var content_f2_18_2351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Pain diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 679px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pain diary is a way to record your child's pain over a period of one week. At the end of each day, you or the child should write down information about the day's pain. The severity is measured on a 0-to-5 scale, with 0 being no pain and 5 being the worst pain imaginable. Triggers can include foods eaten, activities, or feelings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_18_2351=[""].join("\n");
var outline_f2_18_2351=null;
